Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerrAscendHAM:TED +0.20%60 12-1 Month Momentum % is N/A% as of Sep. 02, 2026. GuruFocus rates HAM:TED with a GF Score™ of 60/100 and a GF Value™ of €0.60 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,013 Drug Manufacturers companies, TerrAscend ranks worse than 90.33% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-02), TerrAscend's 12-1 Month Momentum % is N/A%.
The industry rank for TerrAscend's 12-1 Month Momentum % or its related term are showing as below:
HAM:TED's 12-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -15.97 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (HAM:TED) has a 12-1 Month Momentum % of N/A% as of Sep. 02, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on TerrAscend and its competitors. According to the industry distribution chart, TerrAscend ranks #915 out of 1013 companies in the Drug Manufacturers industry, placing it in the top 90.3%.
Is TerrAscend's 12-1 Month Momentum % too high?
TerrAscend's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, TerrAscend ranks #915 out of 1013 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TerrAscend has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's 12-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #915 out of 1013 companies for 12-1 Month Momentum %. This places TerrAscend in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on TerrAscend and its competitors. TerrAscend's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (HAM:TED) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.60, compared to a current price of €0.51 — trading 14.8% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. TerrAscend's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For TerrAscend (HAM:TED), the current 12-1 Month Momentum % is N/A% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (HAM:TED) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of €0.51 is trading 14.8% below its estimated GF Value™ of €0.60.
GuruFocus considers TerrAscend to be Modestly Undervalued.
Key valuation signals for HAM:TED:
12-1 Month Momentum %: N/A%
GF Value™: €0.60 vs. price of €0.51 (14.8% below fair value)
No single metric tells the full story. See the HAM:TED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
60GF Score
Get the complete analysis for HAM:TED
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:TED has been successfully added to your 
